Galapagos Creates New Subscription Right Plan

Core Points - Galapagos NV has created 925,000 subscription rights under a new plan aimed at senior management compensation [1][2] - The subscription rights have an exercise term of eight years and an exercise price of €25.64, with restrictions on early exercise [2] - The total share capital of Galapagos is €356,444,938.61, with 65,897,071 voting rights currently outstanding [3] Summary by Sections Subscription Rights Plan - The Board of Directors approved "Subscription Right Plan 2025 (A)" for personnel, creating 925,000 subscription rights [1] - Each subscription right allows the holder to subscribe to one new share of Galapagos [2] - The rights cannot be exercised before the third anniversary of issuance [2] Financial Overview - Galapagos' total share capital is €356,444,938.61, with 65,897,071 voting rights [3] - There are 11,866,245 subscription rights from various employee plans, excluding the new rights created [3] - Gilead Therapeutics holds a subscription right to maintain a 29.9% shareholding after exercise [3] Company Profile - Galapagos is a biotechnology company focused on addressing high unmet medical needs through innovative science and technology [4] - The company operates in Europe, the U.S., and Asia, aiming to improve patient outcomes and quality of life [4] - Galapagos is committed to delivering best-in-class medicines and has a decentralized cell therapy manufacturing platform [4]